ReviewIndian journal of ophthalmology2026
The AGE-RAGE-oxidative stress axis: A paradigm shift in understanding diabetic retinopathy.
Review in Indian journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Neurodegeneration as an early driver and therapeutic target in diabetic retinopathy.International journal of ophthalmology · 2026Review
- Association between glycated hemoglobin A1c and diabetic retinopathy in adults with type 2 diabetes mellitus residing at high altitudes.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic retinopathy (DR) represents a vision-threatening complication of diabetes, characterized by progressive damage to the retinal neurovascular network in both type 1 and type 2 diabetes. This condition disrupts the delicate cellular interactions within the neurovascular unit (NVU), where advanced glycation end products (AGEs) emerge as key contributors to this dysfunction. While the precise mechanisms of AGE-induced damage remain under investigation, current evidence implicates multiple pathways: the AGE-RAGE signaling axis, oxidative stress generation, inflammatory cascades, and activation of cell death programs. Notably, the irreversible loss of retinal neurons directly correlates with vision decline in diabetic patients, highlighting the urgent need for neuroprotective strategies. Among potential therapeutic targets, AGEs present a promising focus for intervention, given their central role in NVU deterioration. This review helps us in the current knowledge about AGE-mediated neurovascular dysfunction, and it also explores emerging treatment approaches, particularly antiglycation therapies aimed at preserving NVU integrity in DR. It also examines promising preclinical and clinical therapies and identifies critical research gaps-such as the need for better biomarkers of AGE activity and personalized treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.